Misconduct: don't penalize the honest majority of scientists
Sandra Titus and Xavier Bosch suggest that scientific misconduct will be solved by "mandatory and frequent" educational classes for all members of institutions that receive government research funding (Nature 466, 436-437; 2010) . But it is far from clear that the behaviour of the research community has improved since these classes were introduced.
If a politician proposed to solve the nation's crime problem by preaching "mandatory and frequent" sermons on the Ten Commandments to the entire population, few of us would vote for him or her. Bad behaviour rarely happens through ignorance of the law or of the rules that govern research. It arises because of human frailty, and is a feature of every profession and all societies. Individuals are criminals or cheats because they believe that they will not be caught.
Most scientists are honest and well aware of the ethical rules of research. Those who are not -because of inexperience, say -could receive targeted education. But it is unfair and inefficient to penalize the honest and experienced majority by increasing the already onerous regulatory and compliance burden that cripples today's discovery process.
Instead, follow the way society deals with crime: improve detection procedures and punish the guilty. Honest scientists do not need further governmental
Misconduct: don't assume science is self-correcting
Your Opinion pieces propose that research misconduct could be prevented either by financial incentives for teaching research integrity or by informal intervention (Nature 466, 436-437 and 438-440; 2010 
Consumers have a right to affordable genetic testing
There is no good reason for people to have access to their personal genetic information only through medical experts, as Arthur Beaudet suggests (Nature 466, 816-817; 2010) . Such tests provide an incentive for consumers to learn about genetics and to support genetics research, while encouraging them to make reasonably informed decisions about their health.
Consumers have a right to acquire affordable information about their genetic profile. Independent studies could verify the quality of the data gathered, and this could easily be done by product-review organizations such as the US-based Consumers Union.
Regulating the quality of data interpretation would be harder, especially because data-inference models improve over time.
Companies should explain that their models for interpreting genetic material are probabilistic and imperfect. They should also reference the studies used to generate these models and allow users to download the uninterpreted data.
Some companies warn consumers that they should not change their lifestyle if they learn they have a higher risk of a disease. But if a test indicates that a person's risk of developing heart disease is above average, they may exercise more and eat better. Is this any worse than changing your behaviour because your father died of heart disease?
Beaudet suggests that ancestry tests may be acceptable with limited regulation, but that using the same genetic material to infer health-related information should have medical approval. Why should one type of genetic test be acceptable and the other not? Consumers may make life-altering decisions based on that information in both cases, but the fear that this information will harm them is speculative.
Because some genetic tests may have to compete with less expensive, direct-to-consumer products, people calling for a ban on such tests should declare any competing financial interests. You are wrong to dismiss our limited understanding of the consequences of deliberately wiping out 3,500 species of mosquitoes (Nature 466, 432-434; 2010). I would not object in principle to some mosquito extinctions, but your arguments need better ecological insight. To say that "bats feed mostly on moths, and less than 2% of their gut content is mosquitoes" is akin to saying that rice is unimportant in the human diet, based on a sample of visitors to a burger joint. Given that there are around 900 species of insect-eating bat, and mosquitoes in abundance, the insects almost certainly form an important component of some bats' diets.
Christopher Kanan
And how would the mosquitoes be eradicated? The most common control methods -widespread spraying of insecticides, drainage of wetlands and release of alien invasive species -would inflict more than "collateral" damage.
If the risks associated with exterminating some mosquito species turn out to be not too great, then we should keep a small ex situ population for 100 years, say, so that any damage caused could still be undone. 432-434; 2010) would be better for humanity and inflict no more than "collateral damage" on ecosystems, then what else might we reasonably eliminate from the face of the planet -deadly snakes, plague locusts?
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Never mind that the collateral damage of eradicating mosquitoes might include the loss of a group of pollinators and a primary food source for many species. Perhaps another organism will come along to fill the niche eventually -assuming that organisms are replaceable and interchangeable.
In which case, ecologists have to ask what minimum level of biodiversity is required for functional provision of ecosystem services to sustain humanity. 
Fern Wickson

Mosquitoes: first evaluate impacts of eradicating them
We may find ways to limit or even eradicate certain groups of mosquitoes, and it is wise to evaluate the consequences in advance (Nature 466, 432-434; 2010) . We played God with smallpox. Who regrets it?
The idea that mosquitoes preserve nature by keeping humans in check is repugnant and wrong-headed. In the modern era, mortality factors such as malaria do not effectively limit human populations. Reduced fertility is what works. Relieving the burden of malaria will hasten progress to this end.
Jon D. Hoekstra Gainesville State
College, Georgia 30503, USA e-mail: jhoekstra@gsc.edu (Nature 466, 432-434; 2010) . Leaving aside the ethical dilemma and immense technological challenge of extinguishing even one of the many thousands of species of mosquito, our meagre understanding of mosquito biology cannot justify this conclusion.
Information on the population dynamics and community ecology of almost all species of mosquito is scant and based on only a few aspects of their biology. Something is known about the community ecology of some mosquito larvae in microcosms, such as the habitats provided by Nepenthes and Sarracenia pitcher plants, but for those same species almost nothing is known about the community ecology of the eggs, pupae and adults, or their wider ecological role. Even for mosquitoes in these easily managed habitats, the temporal and geographical scales over which an 'extinction experiment' would have to be conducted make it impracticable.
Instead of being diverted to unattainable goals such as extinction, resources should be directed at gaining a fundamental understanding of the population and community ecology of critically important mosquito species.
Stephen M. Smith Department of Biology, University of Waterloo, Waterloo, Ontario N2L 3G1, Canada e-mail: smithsm@sciborg.uwaterloo.ca Medicines Initiative (IMI) -a European public-private partnership to improve pharmaceutical research and development (Nature 466, 306-307; 2010) . This partly reflects a misunderstanding about how knowledge sharing is handled in collaborations between academia and industry.
The IMI is dedicated to creating public-private collaborative networks. Its management of the intellectual-property rights helps the translation of new knowledge into efficient, safe drugs and leads to better standards of health care.
Knowledge generated from each IMI project belongs to the participant who generates it, and comes with negotiated access rights. Non-exclusive licences are privileged. Project participants are free to define the background intellectual property that he or she wishes to make accessible to other project participants.
These rules have proved workable for academics, for smalland medium-sized enterprises, and for many major pharmaceutical companies -in which sensitivities about commercialization and competition run high. So far, 24 small-and medium-sized enterprises and 155 universities are participating in 15 ongoing IMI projects.
Participants in these projects may encounter some bumps on the road to innovation but, as every explorer knows, the unbeaten track often leads to the most rewarding discoveries.
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